Atherosclerosis risk factor management: what's new for the neurologist?

Luciana Dornfeld Bichuette; Marcos Pita Lottenberg; Francisco Akira Malta Cardozo; Daniela Calderaro

doi:10.1590/0004-282X-ANP-2022-S102

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2022; 80(S 05): 88-93
DOI: 10.1590/0004-282X-ANP-2022-S102

CEREBROVASCULAR DISEASE

Atherosclerosis risk factor management: what's new for the neurologist?

Controle dos fatores de risco cardiovascular: o que há de novo para o neurologista?

Luciana Dornfeld Bichuette

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Instituto do Coração, São Paulo SP, Brazil.

,

Marcos Pita Lottenberg

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Instituto do Coração, São Paulo SP, Brazil.

,

Francisco Akira Malta Cardozo

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Instituto do Coração, São Paulo SP, Brazil.

,

Daniela Calderaro

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Instituto do Coração, São Paulo SP, Brazil.

› Author Affiliations

Abstract

ABSTRACT

Stroke is the second leading cause of death worldwide and the vast majority can be attributed to modifiable risk factors, mainly behavioral and metabolic. The top six risk factors responsible for cardiovascular mortality in Brazil in 2019 were high systolic blood pressure, inadequate dietary exposure, high body mass index, high LDL cholesterol, high fasting blood glucose levels, and tobacco. We intend to discuss in this paper the evidence and recommendations in the approach of three essential risk factors for patients with a history of stroke: dyslipidemia, hypertension and diabetes.

RESUMO

O acidente vascular cerebral (AVC) é a segunda causa de morte no mundo e, em grande parte, pode ser atribuído a fatores de risco modificáveis, principalmente comportamentais e metabólicos. Os seis principais fatores de risco responsáveis pela mortalidade cardiovascular no Brasil em 2019 foram pressão arterial sistólica elevada, exposição alimentar inadequada, índice de massa corporal elevado, LDL -colesterol elevado, níveis alterados de glicemia e tabagismo. Pretendemos discutir neste artigo as evidências e recomendações na abordagem de três fatores de risco essenciais para pacientes com histórico de AVC: dislipidemia, hipertensão e diabetes.

Keywords:

Stroke - Atherosclerosis - Risk Factors

Palavras-chave:

Acidente Vascular Cerebral - Aterosclerose - Fatores de Risco.

Full Text

References

References
1 Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG. et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20 (10) 795-820 https://doi.org/10.1016/S1474-4422(21)00252-0
2 Wajngarten M, Silva GS. Hypertension and stroke: update on treatment. Eur Cardiol 2019; 14 (02) 111-115 https://doi.org/10.15420/ecr.2019.11.1
3 Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018; 137 (12) e67-492 https://doi.org/10.1161/CIR.2022s1022022s1020558
4 Hong K-S, Yegiaian S, Lee M, Lee J, Saver JL. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation 2011; 123 (19) 2111-2119 https://doi.org/10.1161/CIRCULATIONAHA.109.934786
5 Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S. et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15 (09) 913-924 https://doi.org/10.1016/S1474-4422(16)30073-4
6 Brant LCC, Nascimento BR, Veloso GA, Gomes CS, Polanczyk C, Oliveira GMM, Flor LS, Gakidou E, Ribeiro ALP, Malta DC. Burden of Cardiovascular diseases attributable to risk factors in Brazil: data from the "Global Burden of Disease 2019" study. Rev Soc Bras Med Trop 2022; 55 (Suppl. 01) e0263 https://doi.org/10.1590/0037-8682-0263-2021
7 Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007; 38 (06) 1881-1885 https://doi.org/10.1161/STROKEAHA.106.475525
8 Hackam DG, Hegele RA. Cholesterol lowering and prevention of stroke. Stroke 2019; 50 (02) 537-541 https://doi.org/10.1161/STROKEAHA.118.023167
9 Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF. et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan stroke study. JAMA 2001; 285 (21) 2729-2735 https://doi.org/10.1001/jama.285.21.2729
10 Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA. et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017; 376 (20) 1933-1942 https://doi.org/10.1056/NEJMoa1609581
11 Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M, Rudolph AE. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (06) 549-559 https://doi.org/10.1056/NEJMoa061894
12 Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376 9753 1670-1681 https://doi.org/10.1016/S0140-6736(10)61350-5
13 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372 (25) 2387-2397 https://doi.org/10.1056/NEJMoa1410489
14 Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722 https://doi.org/10.1056/NEJMoa1615664
15 Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA. et al. Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke 2020; 51 (05) 1546-1554 https://doi.org/10.1161/STROKEAHA.119.027759
16 Lee M, Cheng C-Y, Wu Y-L, Lee J-D, Hsu C-Y, Ovbiagele B. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA Neurol 2022; e215578 https://doi.org/10.1001/jamaneurol.2021.5578
17 Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A. et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol 2017; Jul;109(2 Suppl 1): 1-76 https://doi.org/10.5935/abc.20170121
18 Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016; 57 (08) P1339-P1359 https://doi.org/10.1194/jlr.R067314
19 Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017; 69 (06) 692-711 https://doi.org/10.1016/j.jacc.2016.11.042
20 Kumar P, Swarnkar P, Misra S, Nath M. Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 15660-15660 https://doi.org/10.1038/s41598-021-95141-0
21 Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020; 41 (24) 2275-2284 https://doi.org/10.1093/eurheartj/ehz310
22 van Capelleveen JC, van der Valk FM, Stroes ESG. Current therapies for lowering lipoprotein (a). J Lipid Res 2016; 57 (09) 1612-1618 https://doi.org/10.1194/jlr.R053066
23 Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW. et al. Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL Cholesterol. J Am Coll Cardiol 2021; 78 (05) 421-433 https://doi.org/10.1016/j.jacc.2021.04.102
24 Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382 (03) 244-255 https://doi.org/10.1056/NEJMoa1905239
25 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188 https://doi.org/10.1093/eurheartj/ehz455
26 ClinicalTrials.Gov [Internet]. Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON). 2019. 2022 Mar 12 Available from: https://www.clinicaltrials.gov/ct2/show/NCT04023552
27 Boan AD, Lackland DT, Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke 2014; 45 (08) 2506-2513 https://doi.org/10.1161/STROKEAHA.114.003666
28 SPRINT Research Group. Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM. et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373 (22) 2103-2116 https://doi.org/10.1056/NEJMoa1511939
29 SPRINT Research Group. Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV. et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373 (22) 2103-2116 https://doi.org/10.1056/NEJMoa1511939
30 Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G. et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021; 385 (14) 1268-1279 https://doi.org/10.1056/NEJMoa2111437
31 Xie X, Xu J, Gu H, Tao Y, Chen P, Wang Y. et al. The J-curve association between systolic blood pressure and clinical outcomes in ischemic stroke or TIA: the BOSS study. Sci Rep 2017; 7 (01) 14023-14023 https://doi.org/10.1038/s41598-017-10887-w
32 Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T. et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 2019; 76 (11) 1309-1318 https://doi.org/10.1001/jamaneurol.2019.2167
33 ClinicalTrials.Gov [Internet]. Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients (OPTIMAL Stroke). 2019 modified 2021 Nov 4 2022 Mar 12 Available from: https://www.clinicaltrials.gov/ct2/show/NCT04036409
34 Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D. et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52 (07) e364-467 https://doi.org/10.1161/STR.2022s1022022s1020375
35 Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 02) S14-S21 https://doi.org/10.1007/PL00002934
36 Collaboration Emerging Risk Factors, Sarwar N Kaptoge S. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375 9733 2215-2222 https://doi.org/10.1016/S0140-6736(10)60484-9
37 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41 (02) 255-323 https://doi.org/10.1093/eurheartj/ehz486
38 Tsai W-H, Chuang S-M, Liu S-C, Lee C-C, Chien M-N, Leung C-H. et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 15364-15364 https://doi.org/10.1038/s41598-021-94945-4
39 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373 (22) 2117-2128 https://doi.org/10.1056/NEJMoa1504720
40 Malhotra K, Katsanos AH, Lambadiari V, Goyal N, Palaiodimou L, Kosmidou M. et al. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J Neurol 2020; 267 (07) 2117-2122 https://doi.org/10.1007/s00415-020-09813-4
41 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 9131 837-853
42 Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14) 977-986 https://doi.org/10.1056/NEJM199309303291401